Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week phase 3 study of fluticasone furoate and vilanterol inhalation powder in COPD
2009-013065-25Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and vilanterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by GSK. Primary endpoint: Weighted mean clinic visit FEV1 0-4 hours post-dose on Treatment Day 168. Started Sep 2009; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-013065-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013065-25.